Atlas Trials

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04447573 · UNKNOWN

Trial details

NCT number
NCT04447573
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2020-06-30
Primary completion
2022-08-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.